In Brief: Medtronic/InStent
This article was originally published in The Gray Sheet
Medtronic/InStent: Complete $200 mil. stock merger following approval by InStent shareholders. Under terms of the deal, for which an agreement was announced in March ("The Gray Sheet" April 1, p. 11), Medtronic will exchange 0.3833 shares of its stock for each of the approximately 10 mil. InStent shares, plus options outstanding...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.